News archive
Showing 800 results
June 2018
-
Media Release
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
- New prescribing information to include data demonstrating Cosentyx® (secukinumab) slows progression of joint structural damage associated with psoriatic arthritis (PsA) at Week 24(1)- PsA can lead… -
Media Release
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
-
Media Release
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable (1)Patients had a 65% chance of being relapse-free… -
Media Release
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
-
Media Release
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
-- Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%)-- About two-thirds of… -
Media Release
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
-
Media Release
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
- Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line… -
Media Release
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
May 2018
-
Media Release
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
- Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy… -
Media Release
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
-
Media Release
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
- Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)1-… -
Media Release
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®